Your Trusted Science-backed Resource for Health, Nutrition, Beauty, and Lifestyle since 2012
Ivermectin and Cancer: 15 Anti-cancer Mechanisms of Action (2024 Review)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Introduction
Is ivermectin the future of cancer treatment? This drug was once labeled "horse de-wormer." Today, extensive research reveals it has 15 powerful ANTI-CANCER mechanisms of action. Let’s look at the science behind how it works.
IVERMECTIN AND CANCER: NEW STUDIES (2024)
Bladder Cancer (2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
Lung Cancer (2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
Glioma (2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma
(2024 Kaur et al) - Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy
Multiple Myeloma (2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
(2024 Goldfarb et al) - Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities
(2024 Newell et al) - Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
2023 Sep.23 - Man-Yuan Li et al - Ivermectin induces non-protective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
Prostate Cancer (2023 May - Samy et al) - Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
2022 Nov - Lotfalizadeh et al - The Anticancer potential of Ivermectin: Mechanisms of action and therapeutic implications
2022 Oct - Jian Liu et al - Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
Pancreatic Cancer (2022 Jun - Daeun Lee et al) - Ivermectin suppresses pancreatic cancer via mitochondria dysfunction
2019 Sep Intuyod et al- Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant CholangiocarcinomaIn Vitro
2018 Feb - Juarez et al- The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug (2018 Feb - Juarez et al)
Satoshi Omura at the Kitasato Institute discovered Ivermectin in 1979 and was awarded a Nobel Prize in Physiology or Medicine for this discovery in 2015.
Ivermectin was FDA Approved for human use in 1987 to orally treat onchocerciasis, also known as river blindness, caused by the blackfly-transmitted parasite Onchocerca volvulus
Ivermectin is annually taken by close to 250 million people
most patients treated with Ivermectin have no side-effects other than those caused by the immune and inflammatory responses against the parasite, such as fever, pruritus, skin rashes and malaise
maximum concentration in plasma is reached 4-5 h after its oral administration
its half-life is approximately 19 h and is metabolized in the liver by the cytochrome CYP1A and CYP3A4 complexes, generating 10 metabolites, mostly demethylated and hydroxylated.
Its excretion is mainly by feces and only 1% is excreted in the urine
Ivermectin exerts antitumor effects in different types of cancer.
What this means Clinically:
Chloride channel - Acute myeloid leukemia - induced cell death
Akt/mTOR path - glioblastoma, renal cancer cell lines - inhibition of mitochondrial biogenesis or function, oxidative stress, DNA damage
P2X7 (ICD) overexpression promotes tumor growth and metastases - ivermectin potentiates immunogenic cell death (ICD) in triple negative breast cancer cells
PAK1 (Autophagy) - glioblastoma and ovarian cancer cell lines - Ivermectin promotes autophagy through this pathway
WNT-TCF pathway - glioblastoma, colon cancer, melanoma - Ivermectin exerts anti-proliferative function through this pathway (possibilities to use Ivermectin to block WNT-TCF dependent cancers like breast, skin, lung)
SIN3 Domain - breast cancer (Ivermectin acts as epigenetic modulator to alter gene expression and decrease tumor growth)
NS3 helicase - glioma cells - Ivermectin had anti-tumor effects by acting as helicase inhibitor
In Vitro Studies:
breast cancer, ovarian, prostate, colon, pancreas, head and neck, melanoma - inhibits cell proliferation, induction of apoptosis, autophagy, reversion of tamoxifen resistance, inhibits metastases
glioblastoma - growth inhibition, apoptosis, and anti-angiogenesis
In Vivo Studies (done on immune deficient mice):
acute myeloblastic leukemia - reduce tumor volume up to 70%
glioblastoma - reduce tumor volume up to 50%
breast cancer - reduce tumor volume up to 60%
glioma - reduce tumor volume up to 50% (at 0.24mg/kg), however at human dose equivalent to 0.8mg/kg tumors were not detectable!
colon cancer - reduce tumor volume up to 85%
median dose employed was equivalent to 0.4 mg/kg in humans from 10 to 42 days (oral, intraperitoneal or intra-tumoral)
the in vitro and in vivo antitumor activities of Ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients
2019 Sep Intuyod et al- Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro
Ivermectin studied on cholangiocarcinoma cells that were chemo resistant (gemcitabine)
Ivermectin inhibited cancer cell proliferation and colony formation in a dose and time dependent manner(!)
Ivermectin caused S-phase cell cycle arrest and cell death
Conclusion: “Ivermectin might be useful as an alternative treatment for cholangiocarcinoma, especially in patients who do not respond to chemo.”
specific mechanism of IVM-mediated cytotoxicity in tumor cells is unclear; it may be related to the effect of IVM on various signaling pathways
IVM seems to induce mixed cell death in tumor cells
CONCLUSIONS: Ivermectin selectively inhibits the proliferation of tumors at a dose that is not toxic to normal cells and can reverse the MDR (multi-drug resistance) of tumors.
In healthy volunteers, the dose was increased to 2 mg/kg, and no serious adverse reactions were found
Unfortunately, there have been no reports of clinical trials of IVM as an anticancer drug
large number of research results indicate that IVM affects multiple signaling pathways in tumor cells and inhibits proliferation, IVM may cause antitumor activity in tumor cells through specific targets
Ivermectin regulates the tumor microenvironment, inhibits the activity of tumor stem cells and reduces tumor angiogenesis and tumor metastasis.
It has become increasingly clear that Ivermectin can induce a mixed cell death mode involving apoptosis, autophagy and pyroptosisdepending on the cell conditions and cancer type.
Ivermectin can enhance the sensitivity of chemotherapeutic drugs and reduce the production of resistance. Therefore, IVM should be used in combination with other drugs to achieve the best effect
Colorectal cancer is 3rd most common cancer worldwide, lacks effective therapy
Ivermectin tested on colorectal cancer cell lines
Ivermectin dose-dependently inhibited colorectal cancer growth
promoted cell apoptosis
promoted total and mitochondrial ROS production (reactive oxygen species)
induced colorectal cancer cell S-phase arrest
Conclusion: Ivermectin might be a new potential anticancer drug therapy for human colorectal cancer
2022 Oct - Jian Liu et al - Progress in Understanding the Molecular Mechanisms Underlying the Antitumor Effects of Ivermectin
PAK1 (Autophagy) - Ivermectin, acts as PAK1 inhibitor and inhibits growth of breast cancer, ovarian cancer, glioblastoma and NF2 tumors and involved in cell death in Nasopharyngeal carcinoma and melanoma.
Apoptosis (Caspase Dependent) - Ivermectin induces apoptosis in glioblastoma, chronic myeloid leukemia cells, also breast cancer, ovarian cancer.
Immunogenic Cell Death (ICD - P2X7 signaling) - ivermectin induces cell death in triple negative breast cancer.
YAP1 Inhibition - hepatocellular and cholangiocarcinoma, colorectal cancer, ovarian cancer, gastric cancer - ivermectin exerts anti-tumor effects
WNT Path (cancer progression - differentiation, metastasis, cell senescence, tumor initiation, tumor growth) - Ivermectin inhibits this path - inhibits colon cancer and lung cancer, ivermectin also limits formation of cancer stem cells.
TF3 Path - ivermectin stimulates apoptosis of melanoma cells.
RNA Helicase Inhibition - ivermectin inhibits cell invasion and proliferation of glioma cells
SID Peptide (SIN3A/B) - Ivermectin inhibits breast cancer progression, also restores tamoxifen sensitivity
Akt/mTOR inhibition - Ivermectin inhibits mitochondrial respiration - glioblastoma, CML leukemia (some cancers like breast, leukemia and lymphoma are more metabolically active and depended on mitochondria - more responsive to ivermectin inhibition)
ivermectin is an angiogenesis inhibitor
ivermectin has anti-mitotic activity
In humans, toxicity of ivermectin is very low, no serious adverse reactions have been found in healthy volunteers at dose up to 120 mg (~2 mg/kg) (Reference: GuzzoCA, FurtekCI, PorrasAG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122–1133.)
2023 May - Samy et al - Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
Ivermectin (derivative) inhibits prostate cancer cell viability, migration capacities
Ivermectin induces apoptosis, autophagy (via ROS)
Ivermectin downregulates expression of cancer stem cell markers
Conclusion: Ivermectin has tremendous potential to target metastatic prostate cancer cells and provides new avenues for therapeutic approaches to advanced prostate cancer
2023 Sep.23 - Man-Yuan Li et al - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
Ivermectin was studied on lung adenocarcinoma cells
Ivermectin strikingly impeded colony formation and viability of cancer cells, along with cell proliferation, caused apoptosis and enhanced autophagy
Ivermectin efficiently suppressed cellular growth of lung adenocarcinoma cells in vivo among nude mice
Conclusion
Ivermectin exerts anti-cancer effects through at least 15 different pathways proven in the medical literature, both in vitro and in vivo!
(You get a nice summary of these 15 pathways from the 2021 paper by Mingyang Tang et al.)
First, let’s quickly summarize the anti-cancer mechanisms (a quick summary can be found in 2022 paper by Loftalizadeh et al):
Ivermectin stops cancer cell migration, invasion and metastasis (via PAK1 inhibition - seen in 70% of all cancers, EMT inhibition, RNA Helicase inhibition)
Ivermectin causes cancer cell mitochondrial dysfunction (inhibits mitochondrial biogenesis, increases reactive oxygen species selectively only in cancer cells)
Ivermectin regulates tumor microenvironment (to inhibit tumor growth and progression, via P2X7 path, ICD - mediates immunogenic cell death)
Ivermectin inhibits cancer stem cells (which are responsible for tumor initiation, progression and recurrence)
Ivermectin has anti-mitotic activity (interacts with mammalian tubulin)
Ivermectin is an epigenetic regulator of cancer to inhibit cancer progression (alters gene expression to inhibit cancer progression, SIN3A, EMT)
Ivermectin can overcome tumor multidrug resistance
What cancers can Ivermectin treat?
The top 5 COVID-19 mRNA Vaccine Induced Turbo Cancers are: lymphomas, brain cancers, breast cancers, colon cancers and lung cancers (signals also seen in leukemias, hepatobiliary cancers, testicular cancers, sarcomas and melanomas)
Ivermectin has been shown to kill these cancer cells (in vitro or in vivo):
breast cancer, especially triple negative breast cancer which is often seen in COVID-19 mRNA Vaccinated women and has the worst prognosis.
glioblastoma and gliomas (glioblastomas are often seen in COVID-19 mRNA Vaccinated individuals)
leukemias, both AML and CML (these are the most aggressive and quickly lethal mRNA Turbo Cancers)
colorectal cancer (Stage 4 Colon cancers common in COVID-19 mRNA vaccinated)
hepatobiliary cancers: hepatocecullar carcinoma, cholangiocarcinoma, pancreatic cancer (major signal with COVID-19 mRNA Vaccines)
lung cancer (Stage 4 lung cancers in COVID-19 mRNA Vaccinated)
melanoma (definite signal in COVID-19 mRNA vaccinated)
renal cell cancer (possible signal with mRNA Turbo Cancers) and urothelial carcinoma
ovarian cancer (possible signal with mRNA Turbo Cancers)
There is almost no literature on Ivermectin and lymphomas which are probably the most common COVID-19 mRNA vaccine turbo cancers - this must be investigated.
What dose of Ivermectin to treat COVID-19 mRNA Vaccine Turbo Cancer?
Guzzo et al published a paper in 2022 on the “Safety, tolerability, and pharmacokinetics of escalating high doses of Ivermectin in healthy adult subjects”
The highest dose tested to be safe with no side effects, was 2 mg/kg.
Max concentration in plasma is 4 hours after oral intake
Half life is 18 hours
Dr.David E. Scheim PhD, Blacksburg VA also wrote an interesting article on Ivermectin Safety in Sep.7, 2021 (Source)
Several studies have shown that Ivermectin’s anti-cancer effects are DOSE-DEPENDENT (higher dose = better response)
Warning: not to be taken as medical advice - hypothetical situation: if I was faced with a COVID-19 Vaccine Induced Turbo Cancer or an advanced stage cancer, I would be looking at an Ivermectin dose of 2mg/kg orally, daily or every two days.
Dr. Justus Hope MD published an article on Aug.29, 2023 that discusses anecdotal cases of Stage 4 Colon cancer, Stage 4 Ovarian Cancer responding to Ivermectin with dramatic drop in Tumor markers.
Also mentioned is a “High Dose Ivermectin” regimen of 2mg/kg per day for a doctor with Stage 4 Gallbladder cancer, taken for over a year, with visual side effects for a few days initially which resolved.
Also described is a case of enlarged Prostate suspicious for cancer, and a 5 week Ivermectin 45mg/day regimen that dropped PSA from 89.1 to 10.9 with resolution of nocturnal urinary frequency. For a 100kg man, that is a dose of 0.45mg/kg, significantly lower than the 2 mg/kg safe dose published by Guzzo et al.
The article describes a cancer patient with a neck tumor and lung metastases on a High Dose Ivermectin regimen of 2.45mg/kg daily.
I believe that it is a reasonable hypothesis that COVID-19 mRNA Vaccine Turbo Cancer patients could benefit from High Dose Ivermectin regimens, such as 2mg/kg and we urgently need more research to be done in this area.
(mRNA Vaccine Induced Turbo Cancers such as leukemias, glioblastomas, breast cancers (including triple negative), colon cancers, hepatobiliary cancers, lung cancers, melanomas, renal cell cancers, ovarian cancers, prostate cancers - as there is already evidence in the literature)
Ivermectin Resources Recently, I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. I have two articles and a Video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose IVERMECTIN and CANCER 2024 - NEW STUDIES 2024 Baghli et al - Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol First-in-the-World Ivermectin, Mebendazole and Fenbendazole Protocol in Cancer has been peer-reviewed and published on Sep.19, 2024. Co-authors include Dr Paul Marik and Dr William Makis. 2024 Fan et al - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage ( 2024 Man-Yuan Li et al ) - Ivermectin induces non-protective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells ( 2024 Kaur et al ) - Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy ( 2024 Xing Hu et ...
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed with ...
We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. According to oncologist Dr William Makis: “ This paper is the FIR...
Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Appendix Cancer Breast Cancer Success Stories (11 cases) Brain Cancer (Glioblastoma) Bile Duct Cancer (Cholangiocarcinoma) Bladder Cancer Success Stories (5 cases) Cervical Cancer Colorectal Cancer (11 cases) Esophageal and Stomach cancer Endometrial Cancer (4 cases) Gastric (Stomach) cancer (3 cases) Head and Neck Cancer (3 cases) Kidney Cancer Case Series (8 cases) Liver Cancer (2 cases) Lung Cancer (11 cases) Leukemia (2 cases) Lymphoma (4 cases) Melanoma (Skin Cancer) Multiple Myeloma Myelodysplastic Syndrome Oral Cancer Ovarian Cancer (2 cases) Pancreatic Cancer (9 cases) Prostate Cancer (15 cases) Salivary Gland Cancer Sarcoma (2 cases) Skin ...
Readers ask a variety of questions regarding the use of fenbendazole. This article is mainly a result of those questions and has been in the hopper for quite a while. It is long overdue as it contains items of importance that, if we waited for the appropriate thematic venue to publish them, they might never see the light of day. With that in mind, please accept the following for what it is: a hodgepodge of fenbendazole-related items that are very important to know. Incorporate these bits and pieces into your arsenal of ideas regarding fenbendazole, any unique insights that come to mind please feel free to share. How Safe is Fenbendazole? Is fenbendazole harmful to humans? Due to the long and successful use of fenbendazole as a veterinary antiparasitic medicine since the late 1950s, a wealth of safety data has been acquired that has stood the test of time. According to Drugs.com, there are no commonly used drugs that interact with fenbendazole. Fenbendazole is so safe for veterina...
What is fenbendazole used for in humans? Fenbendazole (also known as fenben) is a veterinary medication used to treat parasites and worms such as tapeworms, hookworms, roundworms, and whipworms, in animals. It is commonly used under brand names like Panacur C and Safe-Guard. If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories. Joe Tippens founded the protocol after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mic...
Transcription (emphasis 2SG - 2nd Smartest Guy): Hi, everyone. Welcome to another episode of 15 minutes with Dr. Makis, my new hard hitting medical podcast. This episode is about fenbendazole and cancer. I will give you the most comprehensive review of the use of fenbendazole in cancer there is. Fenbendazole is an antiparasitic. It is a dog dewormer, has been used It's been used as an antiparasitic since the 1960s, and it has been shown to have extensive anti cancer activity. Now, it's not FDA approved for use in humans. There is a version of it that is almost identical that is approved for use in humans by the FDA, and it's called mebendazole. (2SG: Mebendazole is BigPharma’s money grab whereby they removed a molecule from fenbendazole such that they could egregiously up-charge for a slightly inferior compound based on a bogus patent). I will do a separate video for mebe...
Fenbendazole is a broad spectrum anthelmintic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. One such study found unexpected tumor growth inhibition in a group of mice treated with a combination of Fenbendazole and vitamins. As more studies emerge – some already published, some currently ongoing – a rapidly growing number of human patients are taking Fenbendazole to treat their cancer. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories. Joe Tippens founded the protocol after he was told a story about a s...
The latest weight loss craze to hit Hollywood and beyond is semaglutide, more popularly known as Ozempic, the brand name of the drug marketed to improve blood sugar in people with Type 2 diabetes. Semaglutide is also known as Wegovy, which is prescribed to adults interested in weight loss. The weekly injectable drug is available only by prescription — and costs $1,349 a month (1) — but it’s in high demand among those looking to shed a few pounds. Note: Semaglutide is known by the brand names Ozempic, Wegovy, Rybelsus and others. New York dermatologist Dr. Paul Jarrod Frank told People, "It's the drug of choice these days for the 1%."(2) He says he can always spot users due to "Ozempic face," a gaunt appearance that can occur due to fat loss, which may make you appear older, particularly in the face. But this undesirable side effect is the least of your worries if you choose to use semaglutide. The blockbuster drug, slated to bring in more than $10 billion in ann...
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses. Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to cancer type and stage. Ivermectin dosage should be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. Cancer dosage estimation can be adjusted based on the time that a person has to beat cancer or its risk to the patient - this includes both the cancer type and whether the ca...
Comments
Post a Comment